1. Introduction
===============

Human neutrophils play an important role in the defense system against invasion by microorganisms and in the pathogenesis of various diseases such as rheumatoid arthritis, ischemia-reperfusion injury, chronic obstructive pulmonary disease, and asthma \[[@B1-ijms-16-06532],[@B2-ijms-16-06532],[@B3-ijms-16-06532],[@B4-ijms-16-06532],[@B5-ijms-16-06532]\]. In response to diverse stimuli, activated neutrophils secrete a series of cytotoxins, such as superoxide anion, a precursor of other reactive oxygen species (ROS), granule proteases, and bioactive lipids \[[@B2-ijms-16-06532],[@B6-ijms-16-06532],[@B7-ijms-16-06532]\]. Of these, neutrophil elastase (NE) is stored in the azurophil granules of neutrophils and is released following neutrophil exposure to inflammatory stimuli. High concentrations of ROS and NE have been implicated in the pathogenesis of many acute and chronic pulmonary diseases including asthma, chronic obstructive pulmonary disease, cystic fibrosis, and acute respiratory distress syndrome \[[@B2-ijms-16-06532],[@B8-ijms-16-06532],[@B9-ijms-16-06532],[@B10-ijms-16-06532]\]. Therefore, inhibition of neutrophils activation and the following release of inflammatory mediators provide a promising strategy for the development of potential anti-inflammatory agents.

Many efforts have been devoted to the discovery of novel anti-inflammatory agents for the past few years \[[@B11-ijms-16-06532],[@B12-ijms-16-06532],[@B13-ijms-16-06532],[@B14-ijms-16-06532],[@B15-ijms-16-06532],[@B16-ijms-16-06532]\]. The natural quinones including lapachol, α-lapachone, and β-lapachone (β-LAPA) ([Figure 1](#ijms-16-06532-f001){ref-type="fig"}) were isolated from the heartwood of the Bignoniaceae family (*Tabebuia* sp.) and evaluated for their biological activities. Among them, β-LAPA was found to be able to inhibit the expression of nitric oxide (NO) and PGE~2~ in alveolar macrophages \[[@B17-ijms-16-06532]\]. In order to discover novel drug candidates, we have synthesized certain furo\[3\',2\':3,4\]naphtho\[1,2-*d*\]imidazole derivatives and evaluated for their anti-inflammatory activities. Our results indicated that (*E*)-2-\[2-(5-nitrofuran-2-yl)vinyl)\]-furo\[3\',2\':3,4\]naphtho\[1,2-*d*\]imidazole (1) \[[@B18-ijms-16-06532]\] was capable of inhibiting iNOS expression, with an IC~50~ value of 0.52 μM while 2-(4-methoxyphenyl)furo\[3\',2\':3,4\]naphtho\[1,2-*d*\]imidazole (**2**) \[[@B19-ijms-16-06532]\] exhibited a strongly inhibitory activity on LPS-induced PGE~2~ production, with an IC~50~ value of 0.047 μM. We have also demonstrated that benzo\[*a*\]furo\[2,3-*c*\]phenazinecarboxylic acid (**3**) \[[@B20-ijms-16-06532]\] strongly inhibited superoxide anion generation while 4-(4-methoxyphenoxy)naphthalene-1,2-dione (**4**) \[[@B21-ijms-16-06532]\] was able to inhibit NO and TNF-α released in LPS-induced Raw 264.7 cells. In continuation of our search for novel type of anti-inflammatory agents, the present study describes preparation and biological evaluation of certain benzo\[*f*\]indole-4,9-dione derivatives which belong to a new structural type possessing versatile iminoquinone moiety. Their cytotoxicities were also evaluated due to the structural similarity of these tricyclic compounds to the cytotoxic (*Z*)-4-(hydroxyimino)naphtho\[2,3-*b*\]furan-9(4H)-one (**5**) \[[@B22-ijms-16-06532]\] which exhibited an IC~50~ value of 0.82 μM against the growth of K562 cell.

![Structures of lapachol, β-lapachone, α-lapachone, and compounds **1**--**5**.](ijms-16-06532-g001){#ijms-16-06532-f001}

2. Results and Discussion
=========================

2.1. Chemistry
--------------

Treatment of naphthalene-1,4-dione (**6**) with benzylamine afforded 2-(benzylamino)naphthalene-1,4-dione (**7**) \[[@B23-ijms-16-06532]\] in 78% yield as described in [Scheme 1](#ijms-16-06532-f004){ref-type="scheme"}. Condensation of **7** with acetaldehyde or acetone afforded 1-benzyl-1*H*-benzo\[*f*\]indole-4,9-dione (**8**) and 1-benzyl-2-methyl-1*H*-benzo\[*f*\]indole-4,9-dione (**9**) respectively in a moderate yield. Treatment of **8** with NH~2~OH proceeds in the regiospecific and the stereospecific manners to give (*Z*)-1-benzyl-4-(hydroxyimino)-1*H*-benzo\[*f*\]indol-9(4*H*)-one (**10**) as a sole product. The regiospecific oximination occurred at C-4 rather than C-9 carbonyl was established based on the ^13^C-NMR in which the more downfield C-4 carbonyl shifted from 180.98 to 141.42 ppm while the more upfield C-9 carbonyl shifted from 176.23 to 174.12 ppm \[[@B22-ijms-16-06532],[@B24-ijms-16-06532]\]. The stereospecific oximination to give *Z*-form product rather than the *E*-isomer can be realized in which the hydroxyl group proximate the pyrrole ring is less sterically hindered \[[@B25-ijms-16-06532]\]. Accordingly, compound **11** was prepared from **9** with NH~2~OH.

The known 3-acetyl-1-benzyl-2-methyl-1*H*-benzo\[*f*\]indole-4,9-dione (**12**) \[[@B26-ijms-16-06532]\] was obtained by the reaction of **7** with acetylacetone. Treatment of **12** with NH~2~OH or NH~2~OMe gave 1-benzyl-3-\[1-(hydroxyimino)ethyl\]-2-methyl-1*H*-benzo\[*f*\]indole-4,9-dione (**13**) and its methoxyimino analog **14** respectively. Reaction of **8** and **9** with procainamide proceeds in the regiospecific and the stereospecific manners to afford (*Z*)-4-(1-benzyl-9-oxo-1*H*-benzo\[*f*\]indol-4(9*H*)-ylideneamino)-*N*-\[2-(diethylamino)ethyl\]benzamide (**15**) and (*Z*)-4-(1-benzyl-2-methyl-9-oxo-1*H*-benzo\[*f*\]indol-4(9*H*)-ylideneamino)-*N*-\[2-(diethylamino)ethyl\]benzamide (**16**) respectively in a fairly good overall yield. The formation of *Z*-form product rather than the *E*-isomer can be realized in which the 4-substituted phenyl group proximate the pyrrole ring is less sterically hindered \[[@B22-ijms-16-06532],[@B25-ijms-16-06532]\].

2.2. Biological Results and Discussion
--------------------------------------

Certain benzo\[*f*\]indole-4,9-dione derivatives were synthesized and evaluated for their inhibitory effects on superoxide anion generation and neutrophil elastase (NE) release in formyl-[l]{.smallcaps}-methionyl-[l]{.smallcaps}-leucyl-[l]{.smallcaps}-phenylalanine (fMLF)-activated human neutrophils and results are shown in [Table 1](#ijms-16-06532-t001){ref-type="table"}. 1-Benzyl-1*H*-benzo\[*f*\]indole-4,9-dione (**8**) and its 2-methyl derivative **9** exhibited weak inhibitory effects on superoxide anion generation and were inactive on the inhibition of NE release. (*Z*)-1-Benzyl-4-(hydroxyimino)-1*H*-benzo\[*f*\]indol-9(4*H*)-one (**10**) showed a potent dual inhibitory effect on NE release and superoxide anion generation with IC~50~ value of 2.78 and 2.74 μM respectively. In contrast, its 2-methyl derivative **11** exhibited only marginal activity on superoxide anion generation and was inactive on the inhibition of NE release. These results indicated that the oxime moiety enhanced anti-inflammatory activities while methyl substituent at C-2 position was unfavorable especially in the inhibition of NE release. The same structure-activity relationships were observed in which 3-acetyl-1-benzyl-2-methyl-1*H*-benzo\[*f*\]indole-4,9-dione (**12**) was inactive while its oxime derivative **13** exhibited a weak dual inhibitory effect on NE release and superoxide anion generation. Compound **14**, the methyl derivative of **13**, was inactive. Among these benzo\[*f*\]indole-4,9-dione derivatives, (*Z*)-4-(1-benzyl-9-oxo-1*H*-benzo\[*f*\]indol-4(9*H*)-ylideneamino)-*N*-\[2-(diethylamino)ethyl\]benzamide (**15**) was the most potent dual inhibitor on NE release and superoxide anion generation with IC~50~ value of 0.51 and 2.05 μM respectively. Although (*Z*)-4-(1-benzyl-2-methyl-9-oxo-1*H*-benzo\[*f*\]indol-4(9*H*)-ylideneamino)-*N*-\[2-(diethylamino)ethyl\]benzamide (**16**) exhibited a strong inhibitory effect on superoxide anion generation with an IC~50~ value of 0.52 μM, it induced NE release of human neutrophils.

![Synthesis of benzo\[*f*\]indole-4,9-dione derivatives **8**--**16**.](ijms-16-06532-g004){#ijms-16-06532-f004}

ijms-16-06532-t001_Table 1

###### 

Anti-inflammatory activities of benzo\[*f*\]indole-4,9-dione derivatives in formyl-[l]{.smallcaps}-methionyl-[l]{.smallcaps}-leucyl-[l]{.smallcaps}-phenylalanine (fMLF)-activated human neutrophils (IC~50~ in μM) ^a^.

  Compound           Superoxide Anion   Elastase Release
  ------------------ ------------------ ------------------
  **8**              16.10 ± 1.87       \>30
  **9**              14.04 ± 4.40       \>30
  **10**             2.78 ± 0.89        2.74 ± 1.20
  **11**             7.47 ± 1.39        \>30
  **12**             \>30               \>30
  **13**             10.54 ± 0.52       14.65 ± 2.44
  **14**             \>30               \>30
  **15**             0.51 ± 0.12        2.05 ± 0.21
  **16**             0.52 ± 0.11        -- ^b^
  **LY294002 ^c^**   1.36 ± 0.33        2.21±0.45

^a^ Concentration necessary for 50% inhibition (IC~50~); Results are presented as mean ± SEM (*n =* 3); ^b^ Alone induced elastase release of human neutrophils; and ^c^ LY294002 (a phosphatidylinositol-3-kinase inhibitior) was used as a positive control for superoxide anion generation and elastase release.

These benzo\[*f*\]indole-4,9-dione derivatives were evaluated *in vitro* against a panel of cell lines consisting of MCF7 (breast), NCI-H460 (lung), and SF-268 (CNS) as described previously \[[@B27-ijms-16-06532]\]. Compounds which reduced the growth of any one of the cell lines to 50% or less at the concentration of 4 μg/mL were considered cytotoxic and subjected to further evaluation for their dose--response effects and IC~50~ measurement. Results from [Table 2](#ijms-16-06532-t002){ref-type="table"} indicated compounds **15** and **16** were cytotoxic and their IC~50~ against three cancer cells and a normal cell, Detroit 551, were shown in [Table 3](#ijms-16-06532-t003){ref-type="table"}. The IC~50~ value of compounds **15** and **16** ranged between 3.16 and 27.41 μM and were much less cytotoxic than that of camptothecin (CPT).

ijms-16-06532-t002_Table 2

###### 

Cytotoxicity (% survival rate) of benzo\[*f*\]indole-4,9-dione derivatives at 4 μg/mL.

  Cells\\Compd   8     9     10    11    12    13    14    15    16    CPT ^a^
  -------------- ----- ----- ----- ----- ----- ----- ----- ----- ----- ---------
  MCF7           99    105   110   104   78    106   104   82    57    33
  NCI-H460       96    104   110   110   88    111   108   31    18    1
  SF-268         103   106   106   102   115   109   112   120   106   25

^a^ CPT: camptothecin.

ijms-16-06532-t003_Table 3

###### 

Inhibition of *in vitro* cancer cell lines by benzo\[*f*\]indole-4,9-dione derivatives \[IC~50~ (μM) ± standard deviation\] ^a^.

  Compd\\Cells   MCF7          NCI-H460       SF-268         Detroit 551
  -------------- ------------- -------------- -------------- -------------
  **15**         4.98 ± 0.15   3.16 ± 0.13    27.41 ± 0.39   7.68 ± 0.58
  **16**         4.95 ± 0.21   3.23 ± 0.34    25.76 ± 1.66   4.78 ± 0.57
  **CPT ^b^**    0.57 ± 0.03   0.03 ± 0.003   0.19 ± 0.006   0.99 ± 0.09

^a^ Values representative mean ± standard deviation from three experiments; and ^b^ CPT: camptothecin.

Compound **15** (3, 10 and 30 μM) showed cytotoxicity effects in human neutrophils, as measured by lactate dehydrogenase (LDH) release. In contrast, compound **10**, even at high concentration of 30 μM, showed no cytotoxicity effects in human neutrophils (data not shown). The action mechanisms of **10** in human neutrophils were further investigated. Human neutrophil activations, such as respiratory burst and degranulation, are regulated by Akt and calcium signal pathways \[[@B28-ijms-16-06532],[@B29-ijms-16-06532]\]. Therefore, calcuim and Akt are considered as therapeutic target for developing anti-inflammatory agents. Compound **10** did not alter fMLF-induced phosphorylation of Src (Src family Y416) ([Figure 2](#ijms-16-06532-f002){ref-type="fig"}A). Notably, phosphorylation of Akt (S473) and mobilization of \[Ca^2+^\]~i~ caused by fMLF was inhibited by compound **10** ([Figure 2](#ijms-16-06532-f002){ref-type="fig"}B and [Figure 3](#ijms-16-06532-f003){ref-type="fig"}).

![Compound **10** inhibits phosphorylation of Akt, but not Src, in fMLF-activated human neutrophils. Quantitation of the p-Scr/GADPH (**A**) and p-Akt/Akt (**B**) ratios is shown. Representative images from one of three experiments are shown.](ijms-16-06532-g002){#ijms-16-06532-f002}

![Compound **10** inhibits fMLF-induced \[Ca^2+^\]~i~ increase in human neutrophils. The traces shown are from three different experiments.](ijms-16-06532-g003){#ijms-16-06532-f003}

3. Experimental Section
=======================

3.1. General
------------

TLC: Precoated (0.2 mm) silica gel 60 F~254~ plates from EM Laboratories, Inc. (Darmstadt, Germany); Detection by UV light (254 nm). All chromatographic separations were performed using silica gel (Merck 60 230--400 mesh, Darmstadt, Germany). M.p.: Yamato MP-21 melting-point apparatus (Yamato Scientific Co., Tokyo, Japan); Uncorrected. ^1^H and ^13^C NMR spectra: Varian-Unity-400 spectrometer at 400 and 100 MHz (Varian Inc., Palo Alto, CA, USA), chemical shifts in ppm with SiMe~4~ as an internal standard (=0 ppm), coupling constants *J* in Hz. Mass spectra (HRMS) were recorded on Finnigan/Thermo Quest MAT 95XL (ThermoQuest Finnigan, Bremen, Germany). Elemental analyses were carried out on a Heraeus CHN-O-Rapid elemental analyzer (Austin, TX, USA), and results were within ±0.4% of calculated values.

### 3.1.1. 2-(Benzylamino)naphthalene-1,4-dione (**7**)

To a stirred solution of naphthalene-1,4-dione (**6**, 0.16 g, 1.0 mmol) in EtOH (100 mL) was added benzylamine (0.31 g, 3.0 mmol) and refluxed for 12 h (TLC monitoring). The resulting solution was concentrated in vacuo and the residue thus obtained was purified by flash chromatography on silica gel, using hexane/CH~2~Cl~2~ (1/1) as eluent and crystallized from MeOH to give 0.21 g (80%) of **7** as a red solid. M.p.: 159--160 °C (lit. 160--161 °C) \[[@B23-ijms-16-06532]\]. ^1^H-NMR (400 MHz, CDCl~3~): 4.38 (d, 2H, *J* = 6.0 Hz), 5.79 (s, 1H), 6.23 (br s, 1H, NH), 7.31--7.40 (m, 5H), 7.62 (ddd, 1H, *J* = 7.6, 7.2, 1.6 Hz), 7.73 (ddd, 1H, *J* = 7.6, 7.6, 1.2 Hz), 8.04--8.10 (m, 2H). ^13^C-NMR (100 MHz, CDCl~3~): 46.77, 101.71, 126.19, 126.26, 127.61 (2C), 128.11, 128.99 (2C), 130.46, 132.05, 133.50, 134.76, 135.84, 147.69, 181.832, 183.07.

### 3.1.2. 1-Benzyl-1*H*-benzo\[*f*\]indole-4,9-dione (**8**)

A mixture of **7** (0.19 g, 1.0 mmol), acetaldehyde (0.22 g, 5.0 mmol) and 1.34 g (5.0 mmol) of Mn(OAc)~3~ in acetic acid (20 mL) was heated at 80 °C for 16 h (by TLC monitoring). The reaction mixture was diluted with 100 mL of ethyl acetate and washed with H~2~O (3 × 50 mL), brine (50 mL), dried over anhydrous MgSO~4~, and evaporated in vacuo. The residue was purified by flash chromatography on silica gel, using a gradient of ethyl acetate/hexane (1/15 to 1/12) as eluent and crystallized from MeOH to give 0.15 g (54%) of **8** as a yellow solid. M.p.: 173--174 °C. ^1^H-NMR (400 MHz, CDCl~3~): 5.71 (s, 2H, CH~2~), 6.79 (d, 1H, *J* = 2.8 Hz, 3-H), 6.99 (d, 1H, *J* = 2.8 Hz, 2-H), 7.25--7.37 (m, 5H, Ar-H), 7.65--7.69 (m, 2H, 6- & 7-H), 8.12--8.19 (m, 2H, 5- & 8-H). ^13^C-NMR (100 MHz, CDCl~3~): 52.36 (CH~2~), 108.27 (3-C), 126.49 (2-C), 126.59 (Ar-C), 127.46 (2Ar-C), 128.13 (5-C), 128.91 (2Ar-C), 129.04, 130.37, 130.82 (8-C), 133.06 (6-C), 133.11 (7-C), 133.73, 133.99, 136.39 (Ar-C), 176.23 (9-C), 180.98 (4-C). Anal. calcd for C~19~H~13~NO~2~: C 79.43, H 4.56, N 4.88; found: C 79.49, H 4.55, N 4.88.

### 3.1.3. 1-Benzyl-2-methyl-1*H*-benzo\[*f*\]indole-4,9-dione (**9**)

This was prepared from **7** as described in the synthesis of **8** from **6** with acetone (0.29 g, 5 mmol) instead of acetaldehyde, to give **9** as a yellow solid (crystallized from MeOH) in a 58% yield. M.p.: 139--140 °C. ^1^H-NMR (400 MHz, CDCl~3~): 2.27 (s, 3H, 2-Me), 5.78 (s, 2H, CH~2~), 6.60 (s, 1H, 3-H), 7.06--7.08 (m, 2H, Ar-H), 7.23--7.33 (m, 3H, Ar-H), 7.63--7.67 (m, 2H, 6- & 7-H), 8.09--8.17 (m, 2H, 5- & 8-H). ^13^C-NMR (100 MHz, CDCl~3~): 12.32 (2-Me), 48.67 (CH~2~), 107.80 (3-C), 126.19 (2Ar-C), 126.38 (Ar-C), 126.45 (5-C), 127.57 (8-C), 128.57, 128.86 (2Ar-C), 130.21, 132.81 (6-C), 133.02 (7-C), 133.46, 134.21, 136.35 (2-C), 140.23 (Ar-C), 175.48 (9-C), 181.19 (4-C). Anal. calcd for C~20~H~15~NO~2~: C 79.72, H 5.02, N 4.65; found: C 79.71, H 5.03, N 4.64.

### 3.1.4. 1-Benzyl-4-(hydroxyimino)-1*H*-benzo\[*f*\]indol-9(4*H*)-one (**10**)

To a suspension of **8** (0.29 g, 1.0 mmol) in 2-ethoxyethanol (30 mL) was added hydroxylamine hydrochloride (0.20 g, 3.0 mmol). After reflux for 8 h (by TLC monitoring), the cooled mixture was evaporated in vacuo and the residue was poured into H~2~O (20 mL). The crude product was purified by flash chromatography on silica gel, using MeOH/CH~2~Cl~2~ (1/20) as eluent and crystallized from MeOH to give 0.22 g (73%) of **10** as a yellow solid. M.p.: 202--203 °C. ^1^H-NMR (400 MHz, DMSO-*d*~6~): 5.80 (s, 2H, CH~2~), 7.21--7.34 (m, 6H, 3-H and Ar-H), 7.57--7.69 (m, 3H, 2-, 6- & 7-H), 8.11--8.14 and 8.28--8.31 (m, 2H, 5- & 8-H), 12.76 (s, 1H, NOH). ^13^C-NMR (100 MHz, DMSO-*d*~6~): 51.23 (CH~2~), 111.54 (3-C), 121.71, 123.22 (2-C), 125.62, 125.76 (Ar-C), 126.93 (2Ar-C), 127.42 (5-C), 128.57 (2Ar-C), 128.91 (8-C), 131.26, 132.00 (6-C), 132.21 (7-C), 133.96, 138.28 (Ar-C), 141.42 (4-C), 174.12 (9-C). Anal. calcd for C~19~H~14~N~2~O~2~∙0.1H~2~O: C 75.04, H 4.71, N 9.21; found: C 74.98, H 4.69, N 9.24.

### 3.1.5. 1-Benzyl-4-(hydroxyimino)-2-methyl-1*H*-benzo\[*f*\]indol-9(4*H*)-one (**11**)

This was prepared from **9** as described in the synthesis of **10** from **8**, to give **11** as a yellow solid (crystallized from EtOH) in a 73% yield. M.p.: 259--260 °C. ^1^H-NMR (400 MHz, DMSO-*d*~6~): 2.28 (s, 3H, 2-Me), 5.88 (s, 2H, CH~2~), 7.02--7.04 (m, 2H, Ar-H), 7.16 (s, 1H, 3-H), 7.23--7.34 (m, 3H, ar-H), 7.57--7.68 (m, 2H, 6- & 7-H), 8.10--8.12 and 8.28--8.30 (m, 2H, 5- & 8-H), 12.80 (s, 1H, NOH). ^13^C-NMR (100 MHz, DMSO-*d*~6~): 11.92 (2-Me), 47.80 (CH~2~), 111.73 (3-C), 121.40, 123.22 (5-C), 125.86 (Ar-C), 126.20 (2Ar-C), 126.26, 127.29 (8-C), 128.83 (2Ar-C), 129.02 (6-C), 131.64, 131.88 (7-C), 133.66, 137.78 (2-C), 140.57 (Ar-C), 141.56 (4-C), 173.48 (9-C). Anal. calcd for C~20~H~16~N~2~O~2~∙0.6H~2~O: C 73.43, H 5.30, N 8.56; found: C 73.42, H 5.10, N 8.16.

### 3.1.6. 3-Acetyl-1-benzyl-2-methyl-1*H*-benzo\[*f*\]indole-4,9-dione (**12**)

To a solution of **7** (0.26 g, 1.0 mmol), acetylacetone (0.40 g, 4.0 mmol), and CHCl~3~ (3 mL) in MeOH (20 mL) was added four times with CAN (0.41 g × 4, 3.0 mmol) at 10 min intervals. The result mixture was stirred at room temperature for another 10 min and then diluted with ethyl acetate (100 mL), washed with H~2~O (50 mL × 3), brine (50 mL), dried over anhydrous MgSO~4~, and evaporated in vacuo. The residue was purified by flash chromatography on silica gel, using a gradient of MeOH/CH~2~Cl~2~ (1/100) as eluent and crystallized from MeOH to give 0.24 g (71%) of **12** as a orange solid. M.p.: 135--136 °C. (lit. 237--238 °C) \[[@B26-ijms-16-06532]\]. ^1^H-NMR (400 MHz, CDCl~3~): 2.37 (s, 3H, 2-Me), 2.74 (s, 3H, 3-COMe), 5.84 (s, 2H, 1-NCH~2~), 7.06--7.09 (m, 2H, Ar-H), 7.25--7.35 (m, 3H, Ar-H), 7.66--7.73 (m, 2H, 6- & 7-H), 8.11--8.13 and 8.15--8.18 (m, 2H, 5- & 8-H). ^13^C-NMR (100 MHz, CDCl~3~): 10.92 (2-Me), 31.72 (Me), 48.78 (CH~2~), 123.12, 125.31, 126.23 (2Ar-C), 126.42 (Ar-C), 126.72 (5-C), 127.83 (8-C), 128.99 (2Ar-C), 129.82, 133.01, 133.25 (6-C), 133.42 (7-C), 133.53, 135.51, 142.03 (Ar-C), 176.23 (9-C), 180.74 (4-C), 199.23 (C=O). Anal. calcd for C~22~H~17~NO~3~: C 76.96, H 4.99, N 4.08; Found: C 77.01, H 4.99, N 4.42.

### 3.1.7. 1-Benzyl-3-\[1-(hydroxyimino)ethyl\]-2-methyl-1*H*-benzo\[*f*\]indole-4,9-dione (**13**)

This was prepared from **12** as described in the synthesis of **10** from **8**, to give **13** as a yellow solid (crystallized from MeOH) in a 78% yield. M.p.: 204--205 °C. ^1^H-NMR (400 MHz, DMSO-*d*~6~): 2.12 (s, 3H, 2-Me), 2.21 (s, 3H, 3-C(=N)Me), 5.84 (s, 2H, 1-NCH~2~), 7.12--7.14 (m, 2H, Ar-H), 7.26--7.37 (m, 3H, Ar-H), 7.77--7.81 (m, 2H, 6- & 7-H), 8.01--8.04 (m, 2H, 5- & 8-H), 11.09 (s, 1H, NOH). ^13^C-NMR (100 MHz, DMSO-*d*~6~): 10.17 (2-Me), 16.03 (Me), 48.29 (CH~2~), 119.87, 124.85, 125.98 (5-C), 126.03 (Ar-C), 126.33 (2Ar-C), 127.45 (8-C), 128.83 (2Ar-C), 129.21, 132.94, 133.28, 133.46 (6-C), 133.53 (7-C), 136.48, 139.01, 149.88 (C=N), 174.78 (9-C), 179.87 (4-C). Anal. calcd for C~22~H~18~N~2~O~3~: C 73.73, H 5.06, N 7.82; Found: C 73.56, H 5.04, N 7.76.

### 3.1.8. 1-Benzyl-3-\[1-(methoxyimino)ethyl\]-2-methyl-1*H*-benzo\[*f*\]indole-4,9-dione (**14**)

This was prepared from **12** as described in the synthesis of **10** from **8** and *O*-methylhydroxylamine hydrochloride instead of hydroxylamine hydrochloride, to give **14** as a yellow solid (crystallized from MeOH) in a 79% yield. M.p.: 168--169 °C. ^1^H-NMR (400 MHz, DMSO-*d*~6~): 2.13 (s, 3H, 2-Me), 2.26 (s, 3H, 3-C(=N)Me), 3.88 (s, 3H, NOMe), 5.84 (s, 2H, 1-NCH~2~), 7.13--7.15 (m, 2H, Ar-H), 7.27--7.36 (m, 3H, Ar-H), 7.79--7.82 (m, 2H, 6- & 7-H), 8.02--8.05 (m, 2H, 5- & 8-H). ^13^C-NMR (100 MHz, DMSO-*d*~6~): 10.04 (2-Me), 16.68, 48.29, 61.32, 118.66, 124.85, 126.01 (5-C), 126.08 (Ar-C), 126.38 (2Ar-C), 127.47 (8-C), 128.84 (2Ar-C), 129.36, 132.87, 133.25, 133.53 (6-C), 133.61 (7-C), 136.39, 139.09, 151.19 (C=N), 174.86 (9-C), 179.85 (4-C). Anal. calcd for C~23~H~20~N~2~O~3~: C 74.18, H 5.41, N 7.52; Found: C 74.15, H 5.39, N 7.35.

### 3.1.9. 4-(1-Benzyl-9-oxo-1*H*-benzo\[*f*\]indol-4(9*H*)-ylideneamino)-*N*-\[2-(diethylamino)ethyl\]benzamide (**15**)

To a vigorously stirred solution of **8** (0.29 g, 1.0 mmol) in dry dichloromethane (20 mL) at room temperature was added a 1.0 M solution titanium tetrachloride in dichloromethane (1.0 mL, 1.0 mmol). To the resulting violet solution was added a solution of the procainamide (1.2 g, 5.0 mmol) in dichloromethane (10 mL) followed immediately by dry triethylamine (1.78 mL, 12.4 mmol). Two portions of 1.0 M solution of titanium tetrachloride in dichloromethane (2.0 mL, 2.0 mmol each) were added at 30 min intervals, and then the reaction mixture was poured over 100 mL of cold water and extracted with dichloromethane. The organic layer was dried with MgSO~4~ and evaporated in vacuo. The crude product was chromatographed on a column of silica gel using CH~2~Cl~2~/MeOH (10/1) to give 0.34 g (67%) of **15** as a brown solid. M.p.:152--153 °C. ^1^H-NMR (400 MHz, CDCl~3~): 1.36 (t, 6H, *J* = 7.2 Hz, NCH~2~CH~3~), 3.07 (q, 4H, *J* = 7.2 Hz, NCH~2~CH~3~), 3.17 (t, 2H, *J* = 5.2 Hz, NHCH~2~CH~2~N), 3.85 (q, 2H, *J* = 5.2 Hz, NHCH~2~CH~2~N), 5.32 (d, 1H, *J* = 2.8 Hz, 3-H), 5.68 (s, 2H, CH~2~), 6.67 (d, 1H, *J* = 2.8 Hz, 2-H), 6.94 (d, 2H, *J* = 8.8 Hz, Ar-H), 7.17--7.32 (m, 5H, Ar-H), 7.60--7.68 (m, 2H, 7- & 8-H), 8.09 (d, 2H, *J* = 8.8 Hz, Ar-H), 8.21 (dd, 1H, *J* = 7.6, 0.8 Hz, 5-H), 8.47 (br s, 1H, NH), 8.50 (dd, 1H, *J* = 7.2, 0.8 Hz, 8-H). ^13^C-NMR (100 MHz, CDCl~3~): 9.36 (2C), 35.88, 48.15 (CH~2~), 52.26 (2C), 52.94, 110.21 (3-C), 117.72 (2Ar-C), 123.76, 126.07 (5-C), 126.45 (8-C), 127.30 (Ar-C), 127.85, 128.29, 128.53 (2Ar-C), 128.76 (2Ar-C), 129.13 (2Ar-C), 129.81, 130.80 (6-C), 132.39 (7-C), 132.95, 135.80, 136.77, 151.75, 156.24, 167.43 (4-C), 176.07 (9-C). Anal. calcd for C~32~H~32~N~4~O~2~∙1.9H~2~O: C 71.33, H 6.70, N 10.40; found: C 71.69, H 6.52, N 10.01.

### 3.1.10. 4-(1-Benzyl-2-methyl-9-oxo-1*H*-benzo\[*f*\]indol-4(9*H*)-ylideneamino)-*N*-\[2-(diethylamino)-ethyl\]benzamide (**16**)

This was prepared from **9** as described in the synthesis of **15** from **8**, to give **16** as a yellow solid in a 43% yield. M.p.:138--139 °C. ^1^H-NMR (400 MHz, CDCl~3~): 1.38 (t, 6H, *J* = 7.2 Hz, NCH~2~CH~3~), 2.02 (s, 3H, 2-Me), 3.08 (q, 4H, *J* = 7.2 Hz, NCH~2~CH~3~), 3.11 (t, 2H, *J* = 4.8 Hz, , NHCH~2~CH~2~N), 3.86 (q, 2H, *J* = 4.8 Hz, NHCH~2~CH~2~N), 5.18 (s, 1H, 3-H), 5.77 (s, 2H, CH~2~), 6.94--7.01 (m, 4H, Ar-H), 7.20--7.32 (m, 4H, Ar-H), 7.58--7.66 (m, 2H, 6- & 7-H), 8.12 (d, 2H, *J* = 8.4 Hz, Ar-H), 8.19 (dd, 1H, *J* = 7.6, 1.2 Hz, 5-H ), 8.48--8.50 (m, 2H, 8-H & NH). ^13^C-NMR (100 MHz, CDCl~3~): 9.33 (2C), 12.14 (2-Me), 35.90, 48.40 (CH~2~), 48.48 (2C), 53.23, 109.80 (3-C), 117.72 (2Ar-C), 123.38, 126.07, 126.10 (2Ar-C), 126.33 (5-C), 127.35 (8-C), 127.91, 128.08, 128.76 (2Ar-C), 129.17 (2Ar-C), 130.76 (6-C), 132.12 (7-C), 133.20, 135.51, 136.77, 138.97, 151.65, 156.35, 167.47 (4-C), 175.31 (9-C). Anal. calcd for C~33~H~34~N~4~O~2~∙2.3H~2~O: C 70.77, H 6.95, N 10.00; found: C 70.56, H 6.75, N 9.74.

3.2. Biological Evaluation
--------------------------

### 3.2.1. Preparation of Human Neutrophils

Blood was taken from healthy human donors (20--30 years old) by venipuncture, using a protocol approved by the institutional review board at Chang Gung Memorial Hospital. Neutrophils were isolated with a standard method of dextran sedimentation prior to centrifugation in a Ficoll Hypaque gradient and hypotonic lysis of erythrocytes \[[@B30-ijms-16-06532]\].

### 3.2.2. Superoxide Generation and Elastase Release

Superoxide generation and elastase release were carried out according to the procedures described previously \[[@B31-ijms-16-06532]\]. Neutrophils (6 × 10^5^/mL) were equilibrated at 37 °C for 2 min and incubated with compounds for 5 min. Neutrophils were then activated by fMLF (100 nM) in the pretreatment of cytochalasin B (1 μg/mL for superoxide generation and 0.5 μg/mL for elastase release) for 10 min. Superoxide anion production was assayed by monitoring the superoxide dismutase-inhibitable reduction of ferricytochrome *c.* Elastase release was performed using MeO-Suc-Ala-Ala-Pro-Valp-nitroanilide as the elastase substrate.

### 3.2.3. Western Analysis

Neutrophils were pretreated with compounds for 5 min before being stimulated with fMLF at 37 °C. The reaction was stopped by adding 5 × Laemmli's sample buffer \[[@B32-ijms-16-06532],[@B33-ijms-16-06532]\]. Proteins derived from whole-cell lysates were separated by SDS-polyacrylamide gel electrophoresis (PAGE) using polyacrylamide gels and blotted onto nitrocellulose membranes. Immunoblotting was performed using the indicated antibodies and horseradish peroxidase (HRP)-conjugated secondary anti-rabbit antibodies (Cell Signaling Technology, Beverly, MA, USA). The immunoreactive bands were visualized by an enhanced chemiluminescence system (Amersham Biosciences, Bucks, UK) and detected by Ultraviolet Product (UVP) imaging system (Upland, CA, USA).

### 3.2.4. Measurement of Intracellular Calcium Concentration (\[Ca^2+^\]~i~)

Neutrophils were loaded with fluo-3 AM (2 μM) at 37 °C for 45 min. Cells were preincubated with compounds for 5 min, and then activated by fMLF (100 nM). The change in fluorescence was monitored using a Hitachi F-4500 spectrofluorometer (Tokyo, Japan). The excitation wavelength was 488 nm, and the emission wavelength was 520 nm.

4. Conclusions
==============

We have identified (*Z*)-1-benzyl-4-(hydroxyimino)-1*H*-benzo\[*f*\]indol-9(4*H*)-one (**10**) as a novel structural type of potential anti-inflammatory agent. Compound **10** exhibited dual inhibitory activities on NE release and superoxide anion generation in formyl-[l]{.smallcaps}-methionyl-[l]{.smallcaps}-leucyl-[l]{.smallcaps}-phenylalanine (fMLF)-activated human neutrophils with IC~50~ value of 2.78 and 2.74 μM respectively. Mechanism studies indicated that compound **10** did not alter fMLF-induced phosphorylation of Src (Src family Y416). Notably, phosphorylation of Akt (S473) and mobilization of \[Ca^2+^\]~i~ caused by fMLF was inhibited by compound **10**. Further structural optimization of **10** is ongoing.
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